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SUMMARY
DUCH, D. S., M. P. EDELSTEIN AND C. A. NICH0L. Inhibition of histamine-metabo-
lizing enzymes and elevation of histamine levels in tissues by lipid-soluble anticancer
folate antagonists. Mol. Pharmacol. 18: 100-104 (1980).
Potent inhibitors of dihydrofolate reductase can differ widely in the extent to which they
inhibit histamine N-methyltransferase. This difference in activity provided a basis for
selecting drugs as candidate anticancer agents which would have minimal interference
with histamine metabolism. The drugs were studied in vitro for their effects on histamine
N-methyltransferase and diamine oxidase (histaminase), and in vivo for their effects on
histamine levels. Of the drugs studied, a trimethoxybenzylaminoquinazoline (TMQ, JB-
1 1) and two diaminopyrimidines, 2,4-diamino-5-(1-adamantyl)-6-methylpyrimidine and
metoprine, were found to be the most potent inhibitors of histamine N-methyltransferase
in vitro, having K, values of 7, 50, and 100 nii, respectively. TMQ and methasquin were
potent inhibitors of diamine oxidase, having K, values of 4.1 and 3.7 /LM, respectively. In
vivo, TMQ produced significant elevation of histamine levels in rat brain and kidney. A
dimethoxybenzylpyridopyrimidine (BW 301U), a novel lipid-soluble antifolate being
advanced for study as an antineoplastic agent, was as potent as methotrexate as an
inhibitor of dihydrofolate reductase and had minimal effects on histamine levels in vivo.
The evidence presented suggests that in the design of novel antifolates the effects of the
drugs on histamine metabolism should be determined. The same approach is applicable
to other classes of drugs.
INTRODUCTION
Drug toxicity is frequently a limiting factor in the use
of chemotherapeutic drugs. The toxicity of antifolates
used for cancer chemotherapy is manifest primarily
through effects on the rapidly dividing cells of the bone
marrow and gastrointestinal tract. This toxicity of anti-
folates is related to their properties as inhibitors of di-
hydrofolate reductase, leading to depletion of the reduced
folate cofactors necessary for the synthesis of DNA and
other metabolic functions (1). The folate-related toxicity
of these drugs can be reversed by administration of
calcium leucovorin. However, early clinical trials of sev-
eral antifolates indicated that these compounds also pos-
sessed a significant degree of toxicity, which may not be
folate related.
Clinical evaluation of metoprine as an anticancer agent
indicated that this compound produced CNS,’ cutaneous,
C Abbreviations used: CNS, central nervous system; HA, histamine;
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and gastrointestinal toxicities (2-4). These toxicities sug-
gested to us that metoprine could be acting as an inhib-
itor of histamine (HA) metabolism. Subsequent work (5,
6) has shown that metoprine is a potent competitive
inhibitor of histamine N-methyltransferase (HMT) in
vitro which acts competitively with respect to HA. This
lipid-soluble diaminopyrimidine can cause complete in-
hibition of HMT in vitro at concentrations which can be
attained in body fluids and tissues by doses in the range
used for chemotherapy tests (2, 7). Additionally, a single
oral dose of metoprine caused substantial prolonged ele-
vations of HA levels in vivo, producing a 2.5- to 5-fold
increase in rat brain and a 35- to 45-fold increase in rat
kidney. During clinical studies of the anticancer agent
triazinate, a diamino-s-triazine, CNS, and cutaneous tox-
icities similar to those seen with metoprine were observed
(8, 9). Triazinate was also shown to be a competitive
inhibitor of HMT in vitro (5).
In the central nervous system of mammalian species,
HA is metabolized primarily by methylation of the nitro-
gen in the imidazole ring (10) in an S-adenosylmethio-
nine-dependent reaction catalyzed by HMT. Interference
with this inactivation process by a chemotherapeutic
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(I Trimethoprim, an antibacterial diaminopvrimidine, was inactive at
l0’ M as an inhibitor of HMT (5).
agent could lead to accumulation of HA in the brain with
consequent headache or other adverse effects. In other
tissues and organs, HA which might accumulate because
of inhibition of this pathway can be disposed of by
diamine oxidase (DAO) which is present in many tissues
(11). Since drugs which can inhibit DAO and/or HMT
may have unwanted effects, biochemical screening was
used to select folate antagonists having little or no inter-
ference with these HA-metabolizing enzymes. The same
approach is applicable to other classes of drugs.
Inhibition of HMT has been reported for individual
members of several classes of drugs including antimalar-
isis, anticancer agents, antihistamines, diuretics and local
anesthetics (5, 6, 12-14). Drugs within each class vary
considerably in potency as measured by HMT enzyme
assay. However, their effects on HA levels in vivo were
transient or negative (15, 16). Consequently, it seemed
advisable to examine several types of heterocyclic com-
pounds known to be potent inhibitors of dihydrofolate
reductase in order to select those compounds likely to
have minimal interference with HA metabolism.
The present report shows that several antifolates, in
addition to being potent inhibitors of dihydrofolate re-
ductase, also possess the property of being inhibitors of
HA metabolism and as a result may produce unwanted
side effects. This property is not characteristic of all lipid-
soluble antifolates since BW 301U, a potent lipid-soluble
folate antagonist (17), retains high activity as an inhibitor
of dihydrofolate reductase yet has minimal activity as an
inhibitor of HA metabolism. A preliminary report of this
work has been presented (18).
MATERIALS AND METHODS
Chemicals. [methyl-14C]SAM (sp act, 57.8 mCi/mmol),
[methyl-3HJSAM (sp act, 10.5 Ci/mmol), and [1,4-14CJ-
putrescine (sp act, 96.4 mCi/mmol) were purchased from
New England Nuclear, Boston, Massachusetts; hista-
mine, putrescine, aminoguarndine, S-adenosylmethion-
me, and methotrexate (N- (p- {[(2,4-diamino-6-pteridi-
nyl)methyl]-methylamino) benzoyl} glutamic acid, NSC
740) were obtained from Sigma Chemical Company, St.
Louis, Missouri. Aminopterin (N- {p-[(2,4-diamino-6-
pteridinylmethyl)amino]benzoyl} glutamic acid, NSC
739), triazinate (a-2-chloro-4-[4,6-diamino-2,2-dimethyl-
s-triazine- 1 -(2H)-yl]phenoxyl)-N,N-dimethyl-m-toluam-
ideethanesulfonic acid, NSC 139105), methasquin (N- (p-
[ (2,4-diamino-5-methyl-6-quinazolinyl)methyl} amino]-
benzoyl) aspartic acid, NSC 122870), and TMQ, 2,4-dia-
mino-5-methyl-6-[(3,4,5-trimethoxyaniino)methyl]quin-
azoline, NSC 249008), were provided by the Drug Devel-
opment Branch of the National Cancer Institute, Be-
thesda, Maryland. 2,4-Diamino-5-(1-adamantyl)-6-meth-
ylpyrimidine (DAMP) was a gift from Dr. S. F. Za-
krzewski, Roswell Park Memorial Institute, Buffalo, New
York. Metoprine (2,4-diamino-5-(3,4-dichlorophenyl)-6-
methylpyrimidine, NSC 19494) and BW 301U (2,4-
diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyridopyrim-
idine) are Burroughs Wellcome Company (Research Tri-
angle Park, N.C.) compounds.
Enzyme assays. HMT was partially purified from the
cerebral cortex of bovine brain and assayed as previously
described (5, 6). DAO was partially purified from rat
cecum. Ceca from 20 rats were removed and washed in
physiological saline. The ceca were homogenized in 4 vol
of 0.05 M sodium phosphate, pH 7.2, using a Polytron
homogenizer and centrifuged at 26,000g for 20 mm. The
supernatant was fractionated with ammonium sulfate
and the fraction precipitating between 25 and 60% am-
monium sulfate was retained for further purification.
Following dialysis of the ammonium sulfate precipitate,
the preparation was charged onto a 2.5 x 25-cm column
of DEAE-cellulose which had been equilibrated with 0.01
M sodium phosphate, pH 7.2, washed with the same
buffer, and eluted with a linear gradient from 0.01 M
sodium phosphate, pH 7.2, to 0.01 M sodium phosphate,
pH 7.2, containing 0.5 M NaCl. The active fractions were
pooled, concentrated, and used as the source of enzyme.
DAO was assayed using the method of Okuyama and
Kobayashi (19). Incubation mixtures consisted of 100
mol sodium phosphate buffer, pH 7.2, 0.2 tmol putres-
cine (0.1 .tCi [1,4-’4C]putrescine), enzyme, and where
appropriate antifolate in a total volume of 1 mi. Incuba-
tions were for 20 mm at 37#{176}C.The reactions were ter-
minated by adding 1 ml of 0.5 M borate buffer, pH 10.5,
and 20 tl of 0.01 M aminoguanidine, and the radioactive
product was extracted with 6 mi of toluene. Four millii-
ters of the toluene extract was counted in 10 mi of an
Omnifluor-toluene scintillation mixture.
Kinetic analysis. Kinetic analysis was performed using
the method of Lineweaver and Burk (20). K, values were
calculated from replots as described by Segal (21).
Histamine levels. The effects of drugs on histamine
levels in vivo were determined in male Sprague-Dawley
rats as described previously (5, 6).
RESULTS
The antifolates used in this study are all potent inhib-
itors of dihydrofolate reductase and several have been
studied clinically as antitumor agents. The results pre-
sented in Table 1 show that these antifolates, in addition
to being potent inhibitors of dihydrofolate reductase, also
inhibit the methylation of HA in vitro. The most potent
inhibitors were metoprine, which has also been shown to
be an effective inhibitor of HA metabolism in vivo (5, 6),
TMQ, and DAMP, novel antifolates being advanced for
study as chemotherapeutic agents (22-24). Only metho-
TABLE 1
Inhibition of histamine N-methyl transferase by antifolates
Drug Type of diamino Inhibition (%)
heterocycle  -
10’ iO 10” l0 10’
M M M M M
Metoprine Pyrimidine” 0 30 69 93 98
DAMP Pyrimidine - 34 73 96 98
Triazinate s-Triazine 0 9 46 82 97
Methasquin Quinazoline - - 0 55 94
TMQ Quinazoline 26 80 96 99 -
BW 301U Pyridopyrimidine - - 0 1 1 91
Methotrexate Pteridine - - 0 0 0








a C designates competitive inhibition and NC, noncompetitive inhi-
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bition.
trexate and aminopterin showed no inhibition of HMT
at concentrations up to 1 X i0 M.
In tissues other than brain, HA can also be metabolized
by DAO. The results illustrated in Table 2 show that the
same antifolates which are capable of inhibiting HMT
can also inhibit DAO. In this case, however, methasquin
and TMQ are the most potent inhibitors of the enzyme,
whereas metoprine and DAMP, which were good inhib-
itors of HMT, are relatively weak as an inhibitors of
DAO. Methotrexate and aminoptenn, two antifolates
which were inactive as inhibitors of HMT and which
clinically do not exhibit side effects indicative of inhibi-
tion of HA metabolism, were also inactive as inhibitors
of DAO.
Kinetic analysis of the inhibition of HMT and DAO
by the antifolates most active against these enzymes,
illustrated in Fig. 1 for TMQ, showed that these com-
pounds were competitive inhibitors of HMT, with respect
to HA, and noncompetitive inhibitors of DAO with re-
spect to putrescine. The K, values illustrated in Table 3
show that methasquin and TMQ are potent inhibitors of
both HMT and DAO. In fact, TMQ, with a K1 value of 7
nm, is more than 10-fold more active as an inhibitor of
HMT than is metoprine, a compound shown previously
(5, 6) to be one of the most active inhibitors of this
enzyme in vitro. Metoprine and triazinate, though both
quite potent inhibitors of HMT, were relatively weak
inhibitors of DAO. BW 301U, another novel antifolate
also being developed for use as an antineoplastic agent
(17), had weak activity as an inhibitor of both HMT and
DAO.
A single dose of metoprine is capable of producing a
significant elevation of HA levels in both rat brain and
kidney (5, 6). In vitro, TMQ is a more potent inhibitor of
both HMT and DAO than is metoprine. The results
presented in Fig. 2 show that in vivo TMQ is also capable
of producing elevations of HA levels in rat brain and
kidney. Following a single intraperitoneal dose of 10 mg/
kg, TMQ caused a twofold increase in brain HA levels.
Brain levels were maximally elevated 8 h after adminis-
tration of drug. Kidney levels rose sevenfold, were max-
imal 1 h after administration, and approached control
levels at 8 h. Thus TMQ, like metoprine, is capable of
elevating HA levels in vivo. In contrast to TMQ, admin-
istration of BW 301U at the same dose produced no
elevation of HA levels in brain and less than a threefold
elevation of HA levels in kidney which was of short
duration. HA levels returned to control values 2 h after
administration of the drug. In additional studies not
TABLE 2
Inhibition ofdiamine oxidase by antifolates
Drug Inhibition (%)
l0 M 10 M 10’ M
Metoprine 0 14 30
DAMP 0 29 72
Tnazinate 0 14 43
Methasquin 15 68 92
TMQ 19 66 88
Methotrexate 0 0 16
Aminopterin 0 0 0
FIG. 1. Kinetics of inhibition of histamine metabolizing enzymes
by TMQ.
(A) Inhibition of HMT by TMQ. Key: 0, no inhibitor; 0, 1 x 10’
M TMQ; #{163},2.5 x iO- M TMQ. (B) Inhibition of DAO by TMQ. Key:
0, no inhibitor; 0, 4 x 1 M TMQ; z, 8 x 106 M TMQ. Values are the
means of duplicates for each point.
shown in the present report, BW 301U did not increase
HA levels in rat brain and had even less effect on HA
levels in kidney than in the studies presented above.
DISCUSSION
Histamine has been shown to produce a large number
of adverse reactions whether administered directly or
released endogenously. Elevation of HA levels can cause
intense headache, pain, and itch, decrease in blood pres-
sure, increase in gastric acid secretion, bronchospasm,
dyspnea, metallic taste, vomiting, and diarrhea (25). Dur-
ing clinical trials with metoprine and triazinate, it was
found that the toxicities produced by these drugs in-
cluded headache, respiratory depression, fatigue, weak-
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2 Carl W. Sigel, unpublished observations.
Ftc. 2. Effect of TMQ on histamine levels in rat tissue
TMQ, 10 mg/kg, was administered intraperitoneally as a suspension
in 0.5% Tween 80. (A) Rat brain; (B) rat kidney. Each point represents
the mean ± SE from five animals.
ness, epigastric warmth, dermatological reactions, and
metallic taste (2-4, 8, 9). Although histamine levels in
plasma or cerebrospinal fluid were not measured during
the clinical studies, the symptoms described are consist-
ent with an elevation of HA levels in these patients. It is
a difficult problem, however, to determine the extent to
which CNS effects are associated with an accumulation
of HA or with a drug-induced impairment of folate me-
tabolism. These observations combined with a literature
report on antimalarial agents which are inhibitors of
HMT (12) led to our investigation of the effects of these
drugs on the metabolism of HA.
Metoprine was found to be a potent competitive inhib-
itor of HMT in vitro and was also capable of producing
marked elevation of HA levels in vivo. In the rat, meto-
prime produced a 2.5- to 5-fold elevation of brain HA
levels and a 35- to 45-fold elevation of kidney HA levels.
In the same study, triazinate was also shown to be a
potent competitive inhibitor of HMT in vitro (5, 6).
The present study on the effects of other antifolates
used in the treatment of neoplastic diseases and on HA
metabolism in vitro and in vivo extends the previous
investigations and shows that several of these drugs are
potent inhibitors of HA metabolism. TMQ, metoprine,
DAMP, and triazinate were the most potent inhibitors of
HMT in vitro. Methasquin and BW 301U exhibited less
activity, and methotrexate and aminopterin were ineffec-
tive as inhibitors. Since HA can also be metabolized by
oxidative deamination, the effects of these drugs on the
activity of DAO were also examined. Against this en-
zyme, TMQ and methasquin were the strongest inhibi-
tors, while metoprine, DAMP, triazinate, and BW 301U
were considerably less active. Several other quinazoline
compounds which were tested were found to be potent
inhibitors of both HMT and DAO. Further studies are
needed to determine whether this inhibition is a common
property of compounds having a quinazoline ring. As
with HMT, methotrexate, and aminopterin were inactive
as inhibitors of DAO.
TMQ, like metoprine, was also capable of elevating
HA levels in vivo. Following administration of a single

T)ME(hrs)
FIG. 3. Effect ofBW 301 U on histamine levels in rat tissue
BW 301U, 10 mg/kg, was administered intraperitoneally as a sus-
pension in 0.5% Tween 80. (A) Rat brain; (B) rat kidney. Each point
represents the mean ± SE from five animals.
intraperitoneal injection of TMQ, HA levels were signifi-
cantly elevated in both rat brain and kidney. Kidney
levels were maximally elevated 1 h after drug adminis-
tration, the earliest time point examined, and did not
return to control values until 8 h after the drug was given.
Peak drug levels in kidney corresponded with peak HA
levels.2 Drug concentrations at this time were approxi-
mately 1.7 x i0 M, a concentration high enough to
completely inhibit HMT in vitro. However, HA levels in
brain were not maximally elevated until 8 h after drug
administration. This differential time course of elevation
may be due to the slower accumulation of drug in brain
tissue. Metoprine, which is considerably more lipid-sol-
uble than TMQ (log P, the log of the octanol-water
partition coefficient and a measure of the lipid solubiity,
is 2.82 for metoprine and 0.88 for TMQ), requires 5 h to
reach peak concentrations in brain. HA levels are also
maximally elevated at this time (5, 6). Thus the 8-h time
period required for the maximal elevation of HA levels
in the brains of animals treated with TMQ, a drug less
lipid-soluble than metoprine, may reflect the time re-
quired to accumulate a concentration of TMQ sufficient
to cause the observed increase in HA levels in brain. Due
to technical problems in the extraction of TMQ from
brain, drug levels have not been determined satisfactorily
in this tissue. However, levels of HA in various brain
regions are several orders of magnitude lower than the
Km value of HA for HMT (6). Thus, with a competitive
inhibitor having such a low K, for HMT, significant
inhibition of enzyme activity could be expected at these
substrate levels in the presence of low concentrations of
TMQ. In contrast to TMQ, BW 301U produced no ele-
vation of HA levels in the CNS. In fact, following admin-
istration of BW 301U the levels of HA in rat brain
decreased relative to controls. The reason for this de-
crease is not known, but similar observations have been
made in other studies with this drug, as well as with
other pyridopyrimidines. In the data presented here as
well as in studies not reported, BW 301U produced only
a transient increase (0.5- to 3-fold) increase in HA levels
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in rat kidney. HA levels returned to control values by 2
h.
This inhibition of the methylation of HA could be of
considerable importance in man since it has been shown
that this pathway is the primary route of metabolism of
the amine (26, 27). During clinical studies with meto-
prime, drug levels in plasma reached concentrations of
i05 to 10_6 M within a few hours after oral administration
of the drug (2). Single intravenous doses of triazinate
resulted in serum levels of i05 M or higher for 8 h, and
with repeated doses these serum levels could be main-
tamed (8). Both metoprine and triazinate are quite lipid-
soluble and readily enter the CNS. Following oral admin-
istration of 10 mg/kg metoprine to rats, concentrations
of the drug in brain were approximately 2 x i05 M (7).
Even higher concentrations of triazinate were found in
the brain of a patient who underwent craniotomy for a
brain tumor following a dose of 60 mg/m2 (8). Thus, both
compounds are capable of reaching concentrations in
vivo which are more than sufficient to produce a signifi-
cant inhibition of HMT activity in vitro.
BW 301U and TMQ are also moderately lipid soluble
and would be expected to readily enter brain and other
tissues. The elevation of HA levels in rat brain following
a single intraperitoneal dose of TMQ indicates that this
compound does enter the CNS. BW 301U, which is a
much weaker inhibitor of HMT and DAO than TMQ,
does not elevate brain HA levels and has only slight and
transitory effects on HA levels in the kidney. Although
methasquin, like methotrexate and aminopterin, is a
polar compound and enters the cells by way of the folate
transport system (28), the long intracellular half-life of
the drug relative to methotrexate and aminopterin (29)
may be important in the expression of nonfolate related
toxicities, in this case, the inhibition of HA metabolism.
BW 301U and TMQ are each as potent as methotrexate
as inhibitors of dihydrofolate reductase. However, BW
301U would appear to have an advantage over TMQ by
virtue of its significantly lower inhibition of HA metab-
olism. Moreover, in those cases where methotrexate en-
try is limited, BW 301U would be useful because its entry
into the cell (17, 30), like that ofmetoprine and triazinate,
appears to be by diffusion rather than by the use of the
carrier-mediated folate transport system.
In contrast to inhibitors of HA metabolism which have
been previously studied (15, 16), the lipid-soluble inhibi-
tors of dihydrofolate reductase can rapidly diffuse across
the blood-brain barrier and reach high concentrations in
brain. Independent of their chemotherapeutic potential
for the treatment of brain tumors, those compounds
which are potent inhibitors of HA metabolism now pro-
vide a means of elevating brain levels of HA which may
be useful in assessing the function of HA in the CNS.
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